20th September 2018
article written by
Cell Medica

First neuroblastoma patient successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT)

Ground-breaking Phase 1 trial, GINAKIT2, part of Cell Medica’s collaboration with Baylor College of Medicine and Texas Children’s Hospital Study is evaluating highly innovative CAR-NKT therapy, CMD-501, in children with high risk neuroblastoma NKT cell-based platform holds promise for CAR therapy in solid tumors and as a basis for future ‘off-the-shelf’ CAR therapy HOUSTON and […]

Read Full Article
1st August 2018
article written by
Cell Medica

Cell Medica Appoints New CEO to Drive CAR and TCR Clinical Development and Commercialisation

LONDON and HOUSTON – 1 August 2018 – Cell Medica (or ‘the Company’), a leader in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer (CEO) and Executive Director. His appointment follows founder Gregg Sando’s decision to step down as Chief Executive […]

Read Full Article
1st August 2018
article written by
Cell Medica

Publication of ASPIRE Clinical Trial Results

Cell Medica Announces Publication of ASPIRE Clinical Trial Results All Patients Cleared Adenovirus Infection Following Cytovir ADV™ Treatment The results of the phase 1/2 ASPIRE study of adenovirus-specific T cells (Cytovir ADV) in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) have been published (Ip et al, Cytotherapy, 2018; 20:830-38).   In the ASPIRE study, […]

Read Full Article
13th June 2018
article written by
Cell Medica

Cell Medica Appoints Julia P. Gregory as Non-Executive Director and Audit Chair

HOUSTON and LONDON – 13 June 2018 – Cell Medica (or ‘the Company’), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors. Annalisa Jenkins, Chair of Cell Medica, commented: “The Board […]

Read Full Article